

Apunts Med Esport. 2015;50(188):147-159

**apunts**

MEDICINA DE L'ESPORT

[www.apunts.org](http://www.apunts.org)

## CONSENSUS STATEMENT

## Clinical guidelines for the prevention, diagnosis and treatment of venous thromboembolism in sport

Franchek Drobnic<sup>a,\*</sup>, Antoni Pineda<sup>b</sup>, José Román Escudero<sup>c</sup>, José Manuel Soria<sup>d</sup>, Joan Carles Souto<sup>e</sup>

<sup>a</sup> FC Barcelona Medical Services; CAR (High Performance Centre) Research Department, GIRSANE; Sports Medicine Unit, Sant Joan de Deu Hospital, Barcelona, Spain

<sup>b</sup> Haematology Department, SCIAS, Barcelona Hospital, Barcelona, Spain

<sup>c</sup> Angiology, Vascular and Endovascular Surgery Department, Sta. Creu i Sant Pau Hospital, Barcelona, Spain

<sup>d</sup> Genomic and Complex Diseases Department, Instituto de Investigación Biomédica Sant Pau (IIB-Sant Pau), Barcelona, Spain

<sup>e</sup> Thrombosis and Haemostasis Department, Sta. Creu i Sant Pau Hospital, Barcelona, Spain

Received 15 June 2015; accepted: 10 September 2015

**KEY WORDS**

Deep vein thrombosis;  
Thromboembolic  
disease;  
Heparin;  
Novel oral  
anticoagulants

**Abstract**

The term venous thromboembolism refers to various pathological processes among which deep vein thrombosis, pulmonary embolism, chronic thromboembolic pulmonary hypertension and the thrombotic syndrome. The importance in sports activities is that it is a pathology that requires a long recovery period from 3 to 6 months, and a delayed or unsuccessful diagnosis can cause a more serious illness or even a fatal outcome. Its prevalence in the field of sport is difficult to establish, but empirically it seems to be similar to that of the individual who does not practice sport. However, the field of sport and its environment offers clinical risk conditions to be taken into account, bruising on the vascular bed, rest, travel, dehydration, misguided massage therapy, certain medications or a genetic predisposition, may be factors that precipitate their presence. This guide updates the process, explains the diagnostic protocol and provides prevention guidelines and general treatments, also applied to sport, thinking not only of sport but also the professional and accompanying personnel.

© 2015 Consell Català de l'Esport. Generalitat de Catalunya. Published by Elsevier España, S.L.U. All rights reserved.

\* Corresponding author.

E-mail address: [drobnic@car.edu](mailto:drobnic@car.edu), [franchek.drobnic@fcbarcelona.cat](mailto:franchek.drobnic@fcbarcelona.cat) (F. Drobnic).

**PALABRAS CLAVE**

Trombosis venosa profunda;  
Enfermedad tromboembólica;  
Heparina;  
Nuevos anticoagulantes orales

## Guía de práctica clínica para la prevención, diagnóstico y tratamiento de la enfermedad tromboembólica venosa en el deporte

**Resumen**

El término enfermedad tromboembólica venosa se refiere a varios procesos patológicos, entre los que destacan la trombosis venosa profunda, el tromboembolismo pulmonar, la hipertensión pulmonar tromboembólica crónica y el síndrome posttrombótico. La importancia en nuestro medio reside en que es una patología que precisa un periodo de recuperación largo, de 3 a 6 meses, y que un diagnóstico tardío o no bien realizado puede ocasionar una enfermedad más grave e incluso un desenlace fatal. Es difícil establecer su prevalencia en el ámbito del deporte, aunque de forma empírica parece ser similar a la del individuo que no hace deporte. Sin embargo, el ámbito del deporte y su entorno ofrece condiciones clínicas de riesgo que pueden ser factores que precipiten su presencia, la contusión sobre el lecho vascular, el reposo de los viajes, la deshidratación, la masoterapia mal orientada, ciertas medicaciones o una predisposición genética. La presente guía ofrece una actualización del proceso, se expone la protocolización diagnóstica, las pautas de prevención y de tratamiento estándar y aplicado al deporte, pensando no solo en el deportista sino también en el profesional y en el personal acompañante.

© 2015 Consell Català de l'Esport. Generalitat de Catalunya. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

**Definition**

The term *venous thromboembolic disease* (VTED) covers several pathological processes including *deep vein thrombosis* (DVT), *pulmonary thromboembolism* (PTE), chronic thromboembolic pulmonary hypertension and post-thrombotic syndrome. DVT is the presence of a thrombus in a vein, accompanied by a variable inflammatory response. PTE is the formation of a thrombus inside a vein and its later embolisation in the pulmonary artery, totally or partially blocking it.

In sport, the intrinsic risk of suffering a VTED is similar to that of non-athletic individuals. However, athletes are in a situation that could result in exposure to unusual or a higher number of risk factors such as injuries, travel, immobilisation, haemoconcentration, and polycythaemia. The presence of a genetic hypercoagulability disorder adds a further risk<sup>1</sup> which can then be extraordinarily increased in individuals who fraudulently use certain performance enhancing drugs. On the other hand, thrombophlebitis may be brought about by or expedited by various aetiopathogeneses associated with direct or indirect injury that is accompanied by inflammation of the vessel. The presence of the thrombus may be previous to or a consequence of this inflammation, always aggravating the clinical profile.

**Incidence.** The latest reviews indicate that the incidence of the first episode of DVT among the general population is 1.2/1,000 inhabitants/year and it affects 3-5% of the population. It is the third cause of cardiovascular death after the coronary syndrome and cerebrovascular accidents. The mortality of VTED is 14-17% at three months and that of PTE is 25% at one week. The morbidity is explained by the recurrence of 5-7% of VTED cases at three months; 20% DVT at 5 years and 23% PTE at 5 years, 17-50% post-thrombotic syndrome at one year and 23% at two years, pulmonary arterial hypertension recurrence rate of 1 to 5%<sup>2</sup> and an incidence of severe haemorrhages of 5%<sup>3</sup>.

**Aetiopathogenesis**

VTED is a multifactorial and complex disease where the interaction of genetic, estimated at 60%, and environmental factors, use of contraceptives, pregnancy, immobilisation or cancer, among others, determine the risk of thrombosis for each individual<sup>4</sup>. It is important to stress that genetic factors play a very important role and the exposure to prothrombotic environmental factors will trigger appearance of the event.

The known genetic factors are deficiencies in anti-thrombin-III, protein C and protein S (natural anticoagulants of the blood coagulation cascade), Factor V Leiden mutation and the G20210A mutation in prothrombin or F-II gene. Over the last few years this list has been extended and at present there is solid scientific evidence showing the implication of other genetic disorders in the risk of thrombosis<sup>5</sup>. Based on this scientific evidence, it is essential to evaluate the presence of prothrombotic genetic factors when assessing the risk of thrombosis in an athlete. This is then especially important if they present a personal or family history of venous thromboembolic disease. The integration of clinical and genetic data provides more information for more efficient and personalised diagnosis, treatment and prevention of thromboembolic disease.

The pathogenicity and development of DVT involves three factors known as Virchow's triad: injury to the vein wall, venous stasis and hypercoagulability. Damage to the endothelium means that it loses its capacity to inhibit coagulation and initiate the fibrinolytic process. Stasis due to immobilisation or vein obstruction inhibits the *clearance* and dilution of activated coagulation factors. Finally, the congenital or acquired thrombophilic conditions promote the thrombotic process<sup>6,7</sup>. The factors that may simplify the appearance of transitory DVT are shown in Table 1.

**Table 1** Trigger factors for transitory or acquired venous thromboembolic disease

	Estimated risk
<i>Major trigger factors</i>	
Immobilisation with plaster cast	36.5
Major orthopaedic surgery	16.2
General surgery	9.5
Severe injury	4.8-8.6
Being bedridden	5.6
Autoimmune disease (bout)	3.9-16.4
Pregnancy and postpartum period	4.3
<i>Minor trigger factors</i>	
Long trip of more than 5 hours	2.8
Intake NSAIDs	2.5
Obesity	2.3
Cancer	1.8-2.2
Infections	1.7-2.7
Admission to hospital	1.9
Any serious illness	1.7
Anti-psychotic drugs	1.5-1.8
Chronic kidney failure	1.6-1.9
Negroid	1.6
Environmental pollution	1.5
Tamoxifen / Raloxifene	1.5
COPD	1.4-1.6
Varicose veins	1.4
Diabetes mellitus	1.4
Congestive heart failure	1.4
Oral contraceptives	1.3
Tobacco addiction	1.1-1.5
Hormone replacement therapy	1.2

The estimated risk is reported as a hazard ratio, relative risk or odds ratio. All of them are considered equivalent<sup>44</sup>. Deficient hydration favours any of the above criteria<sup>45,46</sup>.

**Table 2** Probability of the diagnosis of DVT. Wells' criteria

Paralysis, paresis or recent immobilisation of the lower extremities in a plaster cast	+1
Bedridden > 3 days or major surgery with general or local anaesthetic in the last 12 weeks	+1
General swelling of the leg	+1
Unilateral increase of the calf diameter > 3 cm (measured 10 cm below the tibial tuberosity)	+1
Tenderness along line of femoral or popliteal veins	+1
Pitting oedema limited to the symptomatic leg	+1
Dilated collateral superficial veins (non-varicose)	+1
Malignancy (including treatment up to six months previously)	+1
Alternative diagnosis as more likely than DVT	-2
Clinical probability high if $\geq 3$ , moderate if 1-2, and low if = 0.	

## Diagnosis

This is usually through risk assessment, clinical examination and complementary tests<sup>8</sup>.

## Risk assessment

The probability of diagnosing DVT is established by the Wells model for proximal thrombosis<sup>9-11</sup> (Table 2).

There is a classification of risk factors for active athletes that combines those intrinsic to their activity with those related to their quality of physically active individual (Table 3). The genetic risk in patients and family members with a risk of suffering thromboembolic events was studied by considering the factors mentioned in Table 4<sup>5,12</sup>.

## Clinical assessment

The main signs of inflammation are tumour, rubor, heat and pain. *Pain* is usually the first symptom. Of insidious or spontaneous onset and with a sensation of heaviness or tension in the extremity, it is often accompanied by functional difficulty. The *location* varies depending on the affected area. In the case of the lower limbs, it usually appears in the calf region and along deep vein pathways (hollow of the knee, Hunter's canal, and groin). Homans' sign (forceful dorsiflexion of the foot with the knee straight causes pain in the calf and hollow of the knee) only appears in one third of DVT cases, and more than 50% of patients do not show this sign, or it exists without the process<sup>5,13</sup>.

The *oedema* is initially soft and with fovea, affecting regions distal to the venous obstruction. Palpating the muscle, especially the calves, reveals a characteristic *induration*. This hardening should not be confused with oedema of subcutaneous cell tissue typical of other affectations not related to venous disease.

The increased superficial venous network that gradually forms as a result of a mechanism to compensate venous drainage and although it may not be appreciated in the very

## Classification

DVT of lower extremities is classified according to its location as:

### Distal

Including: Calf veins (gastrocnemius), tibioperoneal trunk (posterior tibial and peroneal veins), anterior tibial veins and soleal veins.

Asymptomatic in 75% of cases.

Only 5% give rise to PTE or post-thrombotic syndrome.

Without treatment, 20-30% progress into proximal areas.

### Proximal

Including: External iliac vein, internal iliac vein, common femoral vein, deep femoral, superficial femoral, and popliteal veins.

90% of PTEs are caused by emboli from proximal DVT.

**Table 3** Classification of VTED risk factors (adapted from the PRETEMED Guide) and their possible appearance in active athletes

Factor	Sport	Factor	Sport
<i>Physical</i>		<i>Acute clinical conditions</i>	
Pregnancy		CVA with lower limb paresis	
Age		Dehydration	Yes
Postpartum		AMI	
<i>Life style</i>		Severe acute infection	Possible
Bedridden/immobilised	Accidental	Heart failure	
Smoker	Possible	Injury to lower limb	Yes
Plane travel (> 6 hours)	Yes	<i>Chronic clinical conditions</i>	
<i>Drugs and surgery</i>		Diabetes mellitus	Possible/NL
Oral contraceptives	Feminine	Inflammatory intestinal disease	Possible/NL
Anti-depressants	Possible/NL	Severe decompensated COPD	
Antipsychotic drugs		Hyperhomocysteinemia	
Central venous catheter		HIV Infection	Possible
Erythropoietin		Multiple myeloma	
Aromatase inhibitors	Possible/NL	Nephrotic syndrome	
Pacemaker	Possible/NL	Neoplasias	Possible
Tamoxifen/ Raloxifene		Obesity (BMI > 30)	Possible
Hormone replacement therapy		Thrombophilia <sup>a</sup>	Possible
		Previous DVT	Possible
		Vasculitis	Possible/NL

<sup>a</sup> Genetic risk factors are identified in 87% of patients with thrombosis.

Yes: indicates this factor may be present; Possible/NL: indicates that its presence is possible but not likely.

early phases of thrombosis, may be a clear sign in proximal or somewhat more evolved thrombosis.

As the signs and symptoms are not very specific, and may refer to other acute or chronic affections such as a torn muscle, cellulitis, lymphoedema, certain neurological processes, etc. A careful case history and examination should be worked up accompanied by other methods to simplify diagnosis.

**Table 4** Indications for VTED risk assessment by genetic susceptibility study. *Thromboincode*<sup>®</sup>

<i>Patients with VTED pattern</i>
<i>Patients in an environmental risk situation for thrombosis</i>
<i>Family members of patients with a family history of VTED</i>
<i>Disease suggesting a hereditary component</i>
Idiopathic venous thromboembolism in < 45 years
Recurrent venous thrombosis
Venous thrombosis in uncommon vascular areas
Neonatal purpura fulminans
Warfarin induced skin necrosis
Fetal loss or spontaneous miscarriages
Venous thrombosis in pregnant women
Venous thrombosis in women taking contraceptives
Unexplained arterial thrombosis

## Complementary tests

1. *Echo-doppler of the lower limbs.* The technique of choice for suspected proximal DVT, offering high-sensitivity and specificity in symptomatic patients. Its sensitivity is reduced in distal DVT and in asymptomatic patients, its efficacy being less than ideal in patients with distal, pelvic or recurrent thrombosis.

2. *Basic analysis with blood count, biochemistry and coagulation tests determining D-Dimer.* In this case, normal is considered to be below 500 ng/ml<sup>14</sup>. Studies of its power as an analytical marker of VTED concluded that it has high sensitivity (98-100%) and low specificity (35-39%)<sup>15</sup>. If this is combined with the negative predictive value that could be 98%, this test becomes a useful tool for exclusion diagnosis of DVT, but not for establishing it. For this reason it is a variable forming part of the diagnostic algorithms used at present<sup>16</sup> but which has no value in itself. D-Dimer is exclusively generated by the degradation of stabilised fibrin, whereas fibrinogen degradation products (FDP) may originate from degradation of fibrinogen or destabilised fibrin; the latter producing monomeric D fragments but never D-Dimer<sup>17</sup>. For this reason, D-Dimer is a specific marker of fibrinolytic activity in processes with excessive fibrin formation. However, other pathological processes that are not thrombotic may also cause elevation of D-Dimer<sup>18</sup>. *Possible false negatives.* However, it has a lower predictive value of around 85% in patients with distal or infrapopliteal thrombosis, thrombosis of more than 1 week of progress (the figures may become normal), anticoagulated patients, distal thrombosis and pulmonary embolism in subsegmental arter-

ies. Elevated D-Dimer values will never be sufficient to diagnose VTED. The D-Dimer value is also used to determine the progress of the process<sup>19,20</sup>.

### 3. ECG and Chest Rx.

4. *Angio-magnetic resonance imaging*. A non-invasive thromboembolism diagnostic method with a sensitivity and specificity comparable to phlebography in pelvic and femoral vein thrombosis, offering the possibility of a *combined examination* of the lower limbs and the respiratory system. Useful in patients with plaster casts, during pregnancy and in patients allergic to the iodinated contrast phlebography requires.

5. *Computerised axial tomography (CAT scan)*. A CAT scan with contrast is also a useful test for diagnosing proximal DVT. It allows assessing the location of a previously placed vena cava filter if necessary. In the case of suspected PTE the most suitable procedure is to initially perform an angio-pulmonary CAT scan because of its proven high sensitivity in the diagnosis of pulmonary embolism compared to angiography and ventilation-perfusion scintigraphy.

6. *Determination of the genetic susceptibility*. This determination explains 60% of VTED cases. The presence of any of the indications shown in table 4 justifies its evaluation.

## Algorithm for therapeutic DVT diagnosis (Figures 1 & 2)

The accessibility to ultrasound scans in the field of sport enables accelerating the diagnostic process and so *risk evaluation* and *Echo-doppler* can be performed quickly in the event of clinical suspicion while requesting a D-Dimer determination. On the other hand, it may even be immediate if adequate technology is available. The presence of D-Dimer will only corroborate the previous diagnosis by Doppler Ultrasonography or will provide information about the progress of the process.

## Echo-doppler<sup>21</sup>

This ultrasound imaging technique has become the initial and main diagnostic test for the diagnosis of DVT due to its high-sensitivity and specificity, especially in the proximal venous sector. The most direct and reliable sign is the *impossibility of complete collapse of the vein walls* when compressed with the echographic probe in cross-sectional projection. On occasions it is possible to directly view the texture of the intraluminal thrombus and subjectively determine the age of the thrombus by its degree of echogenicity; the higher the echogenicity, the older the thrombus.

The reliability of the echo-doppler in diagnosis of DVT when dealing with proximal venous sectors (femoral and popliteal veins and large proximal veins of the soleus and gastrocnemius) offers high sensitivity (96%) and specificity (98%). However, when the DVT is limited to the plexus soleus and gastrocnemius veins the sensitivity is reduced (73%)<sup>22</sup>. This low sensitivity in the distal sector means repeating the ultrasound scan one week later whenever it is negative and the clinical suspicion high<sup>23</sup>.

In any examination of medial and distal segments of the plexus soleus and gastrocnemius it is impossible to ensure complete collapse of the wall of each and every soleal-calf vein. This is mainly due to the small calibre of the veins at this level and the difficulty to detect complete compressibility as a direct sign of the presence of a thrombus. Under these circumstances the experience of the examiner becomes extremely important, as does the optimisation of every echo-doppler unit with slow flow rates, the systematic comparison with the asymptomatic contralateral extremity, manoeuvres to effectively increase the flow through expression of the footpad with the extremity inclined, the detection of colour irrespective of the examination angle of the echographic probe (angio or power-doppler) or the selective use of echocontrasts.

Indirect signs of normality are the existence of spontaneous flow or variation of the flow in relation to movements of the diaphragm. These are detectable by B colour mode or doppler spectrum. However, it is only possible to detect them in large diameter veins such as the femoral veins or the ileus-caval venous system. In more distal sectors it is necessary to assess the permeability of the plantar or soleal-calf venous plexus by manual compression or by using a sleeve.

The echographic signs that will help differentiate chronic and acute situations are:


- The vein *does not fully collapse* and it has a *normal diameter*, unlike what occurs in acute DVT when the diameter is larger.
- The vein walls can be seen as *swollen* and poorly defined.
- The thrombotic material inside the vein *is not echolucent or homogeneous* as occurs in acute DVT.
- There are often *replacement venous systems* in the area around the totally or partially occluded vein, with development of collateral venous circulation through unusual anatomical spaces.
- There are *veins with partial occupation of their lumen* showing valvular insufficiency to venous reflux challenges.
- There is an echo-doppler examination report of a previous acute episode that can be compared to the current examination.

The echo-doppler report for an examination of suspected acute DVT should indicate:

- Whether the *absence of collapse of the vein wall is complete or partial*.
- Whether the *diameter of the vein is increased compared to the contralateral extremity*.
- Define the *vein sector affected* by the thrombosis and its *proximal and distal extension*.
- Define the *echographic characteristics of the thrombus* (echolucent or echogenic).

However, remember that the clinical criteria of Wells' risk stratification, together with the determination of D-Dimer, enable good diagnostic efficacy for DVT of the lower extremities in Emergency Rooms. In the event of low clinical probability with D-Dimer negative, the performance of





**Figure 1** DVT diagnostic algorithm in the athlete. The accessibility of Ultrasonographic diagnosis facilitates the application of this technique in an early stage. Sport physician must familiarize with the exploration of the vascular territory for this purpose.

Doppler Ultrasonography is unnecessary as it can be assumed to be negative for the diagnosis of DVT in the lower extremities<sup>24</sup> (Figure 2)


## Complications

### Pulmonary thromboembolism

The greatest complication is a PTE and this may occur from important veins such as those in the legs, pelvis, abdomen, arms or neck. The annual incidence of PTE is 0.1%; ranging between 0.01% in young adults up to 1% in the over 60 age group, and causes de high morbidity and mortality<sup>25,26</sup>. More than half of these events originate as DVT. On the other hand, we are faced with a situation with high mortality derived from underdiagnosis. Only one of every three deaths from pulmonary embolism is diagnosed before death, and when this occurs and the condition is treated adequately, the mortality rate drops considerably. It should be taken into consideration in the event of any important bruising in these regions and appearance of symptoms indicating the process. PTE may only appear with dyspnoea and/or tachypnoea at rest or slight effort, sometimes in addition to tachycardia and in some cases chest pain and/or haemoptysis.

### Recurrence of DVT

Patients who are anticoagulated for brief periods (6 to 12 weeks) for uncomplicated calf DVT have a 20% risk of progression of the thrombus to proximal DVT. The risk of recurrence is 8 to 30%, and that of developing post-thrombotic syndrome 1.8 to 20%. Long term oral anticoagulation implies a risk of severe haemorrhage of up to 5% annually (Khan 2015). This type of anticoagulation to prevent re-



\* The options to repeat the Echo-doppler at one week depend on clinical and analytical criteria or always repeat it. In the context of sport apart from determining the clinical risk and D-Dimer, it should always be repeated.

**Figure 2** Evaluation of suspected DVT in ambulatory medicine.

currence should be considered in patients with a previous history of thrombosis or congenital or acquired susceptibility.

## Treatment

The treatment will depend on the diagnostic indications and combined with pharmacological anticoagulation and general measures<sup>27</sup>.

### Superficial vein thrombosis or thrombophlebitis

- Hospital admission not required, although it may be recommended in recurrent cases to dismiss Trousseau's syndrome (migratory thrombophlebitis associated with neoplastic processes).
  - Low molecular weight heparin (LMWH):
    - Without affectation of the saphenous arch (Clexane 40 mg, Fragmin 5,000 IU, Hibor 3,500 IU, Innohep 4500, all every 24 hours with a minimum duration of 7-10 days.
    - In the event of affectation of the saphenous arch, 3 months anticoagulation is recommended and an appointment with a haematologist.
  - Analgesia.
  - Relative rest.
  - Use of graduated elastic compression stockings.

### Confirmed deep vein thrombosis

- Outpatient treatment except for the reasons shown in Tables 5-7.
  - Prescribe VKA (vitamin K antagonist) with INR therapeutic interval between 2-3; new oral anticoagulants (NOACs) or LMWH adjusted to the patient's weight (Table 8)<sup>28,29</sup>.
  - Use of compression stockings to the root of the affected limb, avoiding excessive compression and varying it depending on the progress of the oedema<sup>30</sup>.
    - Analgesia.
    - Active mobilisation of the affected extremity should be initiated as soon as possible. Rest should be relative as of the first day of hospitalisation: although the need has not been demonstrated, it should be adjusted depending on the pain and oedema (adjust days depending on the stage of the thrombus as determined by a specialist in Echo-doppler).
    - When beginning activity: (i) protect the individual from direct or indirect injuries that require a level of haemostasis within normal limits; (ii) prevent high intensity isometric exercises of the affected extremity or any that require a considerable increase diaphragm pressure; (iii) determine the degree of activity depending on the recovery process as determined by additional tests (Dimer D, thrombus quality) and the anticoagulation level and associated aspects that characterise normal physical activity. Table 9 shows the standard recommendations in this regard until considered fit to compete<sup>31</sup>.

### Duration of the treatment

In patients with a transient trigger (Table 1) recurrence is lower (3%), compared to a spontaneous event (10%). Treatment

**Table 5** Exclusion criteria for outpatient treatment

Exclusion criteria	
Absolute	Lack of collaboration or follow-up difficulties Intense pain Patients with suspected severe underlying illness or malignancy High risk of haemorrhage: Malignant HBP, peptic ulcer, recent surgery, altered coagulation, thrombocytopenia Phlegmasia cerulea or alba dolens Severe illness requiring hospitalisation
Relative	Patients without clear diagnosis Suspected pulmonary embolism Suspected rapid progression or thrombosis of the inferior vena cava Post-thrombotic syndrome Allergy, contraindication or limitations on the use of low molecular weight heparin: Thrombocytopenia, morbid obesity PTE relapse Fibrinolytic treatment Pregnant women Risk of recurrent DVT (previous DVT, pregnancy) Bilateral DVT

over 3 months with vitamin K antagonist (VKA), NOACs or LMWH reduces the risk of recurrence by 90%. In patients with greater risk factors, such as surgery, the risk of recurrence is < 3% and so treatment can be suspended after 3 months. In moderate patients, the risk is somewhat higher (5%), and so consideration should be given to maintaining treatment up to 6 months as the risk of haemorrhage is 2% at one year.

That is, in an athlete who presents VTED treatment should be maintained for at least 3 months and consideration given to duration of up to 6 months.

**Table 6** Contraindications for anticoagulation

Absolute	Relative
Severe active haemorrhage	Imminent or recent surgery
Recent intracranial haemorrhage	Serious injury
Severe uncontrolled HBP	Recent birth
Dissecting aortic or cerebral aneurysm	Severe anaemia
Uncorrected coagulation disorders	Active ulcerous disease.
	Pericarditis or pericardial effusion
	Pericarditis o vessament pericardic

**Table 7** Criteria for anticoagulation in outpatient treatment

	LMWH	NOACs
Administration	Subcutaneous	Oral
Treatment adherence	Adequate with risk	Good
Anticoagulation level	Good	Good
Half-life	½ to 3 h	12 h
Duration of action	Up to 12 h	> 24 h
Antidote	Yes (protamine)	No
Risk haemorrhage bruising-certain sporting activities	Low and controlled with suitable doses	Exists. No activity with contact or risk of collision is recommended
Possible minor surgery in ICU	Yes	Complicated
Contraindications	Table 8	Table 8
Pharmacological interactions	PG synthesis inhibitors and antiplatelet agents	Table 11

## Prevention

### Calculation of the probability of a correct diagnosis (Table 2)

In low risk patients: No special measures.

Patients at risk of VTED: LMWH at preventive doses, or thrombin and factor Xa inhibitors or vitamin K antagonists.

In athletes the decision to use LMWH or NOACs will depend on the experience of the medical team and the type

**Table 9** Reference model until considered fit to compete after initiating anticoagulation

Week 1 to 3	Progressive return to everyday life
Week 4	Initiate activities without load (e.g. swimming)
Week 5	Initiate exercises without impact (closed chain) <sup>a</sup>
≥ 6 weeks	Initiate the exercises with impact (open chain) <sup>b</sup>

<sup>a</sup> Bicycle, ergometric exercises.

<sup>c</sup> Jogging, skipping, games...

Adapted of Partsch & Blättler<sup>30</sup>.

of sport played. Table 10 shows the concepts in relation to the possible use of one or another and the interactions with certain treatments or nutrients are shown in Table 11.

For example: With NOACs, any sporting activity with an adversary or the possibility even though remote of a bruise, advise against performing this activity. With LMWH one administration at night permits morning training with guarantees, as does administration in the morning for evening training.

### General measures and evidence level (Table 12)

#### Activity

Immobility *increases the risk of DVT 10 fold*<sup>32</sup>. The mobility of the muscles of the lower limb should be stimulated to prevent the formation of thrombi. Leg exercises reduce venostasis and should be recommended (Evidence I and II-1). This requires:

- *Walking*. When travelling by plane or train, walk for at least five minutes every hour along the aisles of the plane

**Table 8** Pharmacological measures for the prevention of DVT

Generic name	Trade name	Dose/day	Contraindications
<i>LMWH</i>			
Bemiparin	Hibor®	3,500 U (0,2 ml)/24 h	Allergy, thrombocytopenia, haemorrhages
Dalteparin	Fragmin®, Boxol®	5,000 U/24 h	
Enoxaparin	Clexane®, Decipar®	40 mg (0,4 ml)/24 h	
Nadroparin	Fraxiparina®	3,800 U (0,4 ml) < 70 kg U (0.6 ml) > 70 kg	
Tinzaparin	Innohep®	3,500 U (0.35 ml) < 70 kg U (0.45 ml) > 70 kg	
<i>Indirect factor Xa inhibitors</i>			
Fondaparinux	Arixtra®	2,5 mg	Allergy, active haemorrhage, acute bacterial endocarditis, severe acute kidney failure
<i>NOACs</i>			
Table 10			

DVT: deep vein thrombosis; LMWH low molecular weight heparin.



**Table 10** Indications for new oral anticoagulants (NOACs) approved by the European Medicines Agency in adult individuals without impaired renal function or haemorrhagic risk

	Dabigatran Pradaxa®	Rivaroxaban Xarelto®	Apixaban Eliquis®
Prevention of venous thromboembolism in scheduled orthopaedic surgery	Initial dose of 110 mg and then 220 mg/24 h	10 mg/24 h	2.5 mg/12 h
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of DVT and PE relapse in adult patients	150 mg/12 h	15 mg/12 h 3 weeks, then 20 mg/24 h	5 mg/12 h
Prevention of stroke and systemic embolism in patients with atrial fibrillation	150 mg/12 h	20 mg/24 h	5 mg/12 h

Source: Mateo<sup>28</sup>.

or carriage. When travelling by car or coach, stop every hour and take advantage of the opportunity to walk.

• *If the sitting position must be maintained, an attempt should be made to activate the muscles.* Bend the knees, move the feet by flexing, stretching or rotations, press the feet progressively against the floor, alternating one, the other, and both at the same time.

### Hydration

Haemoconcentration increases the viscosity of the blood and reduces flow, especially in the deep veins in the legs of immobile patients<sup>33,34</sup>, good hydration should be ensured (Evidence II-3).

### Mechanical methods

Mechanical methods that ensure passive mobilisation of the lower limbs, imitate muscle contractions and increase the venous flow volume and speed<sup>35</sup>.

- Graduated elastic compression stockings (GECS) (8-18 mmHg).
- Intermittent pneumatic compression (IPC) (pre- and post-surgery).
- Mechanical pumps for the feet (pre- and post-surgery).

Mechanical methods are indicated in patients with increased risk of bleeding, thus making pharmacological prevention hazardous. They are contraindicated in patients with a risk of ischaemic skin necrosis or peripheral neuropathy.

*Graduated elastic compression stockings (GECS).* A meta-analysis of randomised controlled studies of DVT prevention<sup>36</sup> found that it occurred in 8.6% of patients treated compared to 27% of controls (OR 0.34; 95% CI 0.25, 0.46)<sup>12</sup>, and so GECS can be said to be effective in the prevention of DVT in surgical patients (Evidence I) with stockings up to above knee height being preferred. The effectiveness of GECS increases significantly when combined with pharmacological prevention (Evidence I).

One multicentric observational study found that the combined method is more effective than pharmacological prevention alone<sup>37</sup> (Evidence II).

*Intermittent pneumatic compression (IPC)* (pre- and post-surgery). Not described in this review.

*Mechanical pumps for the feet* (pre- and post-surgery). Not described in this review.

### Prevention of VTED in sport

*Patient.* The athlete and companions with clinical conditions of risk applied to the field of sport, should include the presence of genetic factors as a risk condition (Table 13).

*Consideration.* The athlete may suffer important injuries that compromise venous flow to a greater or lesser degree and trigger an inflammatory process in the vessel with the

**Table 11** Pharmacological interactions of NOACs applicable to the three in general

Reduce the effect	Attitude
Rifampicin, St. John's wort (Hypericum), Carbamazepine, Phenytoin	No association
Increase the effect	Attitude
Azole antimycotics (ketoconazole, itraconazole, voriconazole, posaconazole)	Do not associate
HIV protease inhibitors (ritonavir and similar)	Do not associate
Anticoagulant drugs	Do not associate
Macrolide antibiotics (Erythromycin, Clarithromycin)	Precautions
NSAID	Precautions
Acetylsalicylic acid or clopidogrel	Precaution. Increase risk of bleeding
Quinidine	Precautions
Amiodarone	Precautions
Verapamil	Reduce dose

Source: Mateo<sup>28</sup>.

**Table 12** Evidence level considered to establish recommendations in accordance with the United States Preventive Service Task Force (USPSTF)

I	Evidence obtained from at least one well-designed randomized controlled trial
II-1	Evidence obtained from well-designed controlled trials without randomization
II-2	Evidence obtained from well-designed case-control and cohort studies, preferably from more than one centre or research group
II-3	Evidence obtained from multiple time series designs with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence
III	Opinions of respected authorities based on clinical experience, descriptive studies, or reports from expert committees

consequent procoagulant alteration limiting anticoagulant activity. These affections may be of certain importance on musculotendinous tissue and blood vessels of the area, especially if they occur on the leg, ankle or foot as on many occasions they require immobilisation and a certain period of rest. Up to 34% of Achilles tendon ruptures result in DVT, irrespective of whether they are operated on or not<sup>38</sup>. In other cases the need for surgical, diagnostic or remedial tests for example in knee arthroplasty, the guidelines for surgical prevention provide limited practical orientation as, depending on the series presented, the prevalence covers a very wide range and it is not clear how to transfer the results of randomised studies into clinical practice, as a large number of cases of VTEDs are luckily limited by routine prevention when available and are asymptomatic distal DVT. Therefore, there is no consensus regarding the real application of pharmacological prevention actions, and so patients subjected to knee arthroscopy should be managed on an individual decision based on VTED risk assessment instead of a general protocol<sup>39</sup>. A recent study to assess the incidence of DVT in subjects undergoing arthroscopy for reconstruction of the ACL reported an incidence of DVT in 12% during the first week, higher than when the surgery is to repair other structures at the same time. In summary, the incidence increases by about 5% for every 30 min of tourniquet application. This means it is 5.6% if this time is < 90 min; 12.8% if between 90 and 120 min, and 17.4% if this time exceeds 120 min<sup>40</sup>.

Consideration should also be given to the fact that participating in any sport implies a certain degree of dehydration with the consequent increase of blood viscosity, especially if the athlete cannot, or does not know how to, hydrate themselves well, or there is very abundant fluid loss. It is not unusual for travel to take place soon after the competition. Planes or cars/coaches are vehicles that do not allow for walking for a certain period of time. National flights and bus travels usually last less than two hours, a more than reasonable time to stop and take a rest. Plane trips also have the inconvenience, apart from venous stasis,

of being a place where there is a tendency to dehydration due to the low moisture content of the environment<sup>41</sup>. This aspect should be taken into consideration by athletes during the flight. In regard to height and hydration, it is interesting to note that sports performed at high altitude combine several susceptibility factors, which in themselves have no great influence, but it is not known whether their combination creates an environment favourable to the presence of VTED, hypoxia, dehydration, haemoconcentration, low temperature, tight clothing, reduced mobility, age, previous long trip<sup>42</sup>. Any suspicious process should alert to an early diagnosis, and any subject with a history should assess their genetic susceptibility (Table 14).

Finally, it should be remembered that there are ergogenic substances such as anabolic steroids, growth hormones, blood concentrate transfusions, the use of erythropoietin, etc.<sup>43</sup> whose aim is to preserve the athlete's health and guarantee clean competition but which are considered performance enhancing drugs and not expected to be found, but unfortunately they are not infrequent in various areas of physical work, almost always acquired illegally, and causing a kaleidoscope of serious diseases where VTED is highly present. If these conditions affect more predisposed or associated with certain activities individuals it should be studied, since there seems to be an alarming prevalence of presentation of pulmonary embolism in basketball<sup>47</sup>, with associated probability individual idiosyncrasies, this event does not occur or does very differently and less conspicuous in professional football<sup>48</sup>. In the first case, it is possible that the characteristics of sport than those that predispose and facilitate, but select subjects that have them and they are also the result of a lability to present VTE, where the sport environment makes them proof.

On trips of more or less 2\* hours, it is necessary to make sure to:

- *Walk*. When travelling by plane or train, walk for at least five minutes every hour along the aisles of the plane or carriage. When travelling by car or coach, stop every hour and take advantage of the opportunity to walk.
- If the sitting position must be maintained, an attempt should be made to *activate the muscles*. Bend the knees, move the feet, flex/stretch and rotate the ankles, press the feet progressively against the floor, alternating one, the other, and both at the same time.
- Avoid tight clothing, strong elastics and creases in areas of flexion (Evidence III).
- Drink liquid (non-alcoholic) often and regularly. Hydrate well (Evidence II-3).

On trips of more than 2\* hours *in addition to the above* make sure to:

\* Considering trips of about two hours is an empirical decision based on the maximum duration of flights in Spain or even continental Europe. The majority of trips by coach may exceed this period, although not always reaching the limits of the regulations regarding current driving times and rest periods, EC Regulation No. 561/2006, "Breaks of at least 45 minutes should be taken after four and a half hours at the latest".

Table 13 Clinical risk conditions for DVT applied to sport

Possible conditions present	High level athlete	Companion / Sport environment	General athlete
Over 40 years of age	No	✓	✓
Prolonged immobilisation or paralysis	Travel/injury	Travel	Travel/injury
Injury to the vascular	✓	No	✓
Previous venous thromboembolic disease	✓	✓	✓
Presence of genetic factors	✓	✓	✓
Major surgery (abdomen, pelvis, lower limbs)	✓	✓	✓
Obesity	No	✓	✓
Varicose veins	✓	✓	✓
Congestive heart failure	No	✓	✓
Myocardial infarction	No	✓	No
Cerebrovascular accident	No	No	No
Fracture of the pelvis, hip or legs	✓	✓	✓
Femoral venous catheter	No	No	No
Inflammatory bowel disease	✓	✓	✓
Nephrotic syndrome	No	✓	No
Estrogen use	✓	✓	✓
Cancer	No	No	No
Haemostasis abnormalities	✓	✓	✓
Anomalies de l'hémostase	✓	✓	✓

- Walk > 5 minutes every hour (Evidence II-2).
- Bend the ankles and knees often (Evidence II-2).
- Occasionally raise the legs (above hip level) (Evidence II-2).

If there is a risk of venous thrombosis:

- Use progressive compression stockings (Evidence II-3).
- Take an oral anticoagulant under medical prescription.
- LMWH at preventive doses (Evidence I).

In summary, the recommendations are: *be well hydrated, move often*, and, if there is any susceptibility, use *progressive compression stockings or even LMWH* at preventive doses.

## Conflict of interests

The authors of this have no conflict of interests. They have no contractual relationship with, nor any personal economic interest in any of the companies whose substances may be mentioned in this text/guide.

## References

1. Meyering C, Howard T. Hypercoagulability in athletes. *Curr Sports Med Rep*. 2004;3:77-83.
2. S&H Medical Science Service. Campo Martín A, editor. Estudio sobre la Enfermedad Tromboembólica Venosa en España. Sociedad Española de Medicina Interna (SEMI); 2006.
3. Khan F, Datta YH. Risk of bleeding during long-term anticoagulation with warfarin: A tertiary care center experience. *Blood Coagul Fibrinolysis*. 2015;26:110-2.

Table 14 Basic risk factors in the athlete and their prevention

Table 14a Risk factors

1. Injury to the vein (or artery): bruising, laceration, stretching
2. Related facilitating factors:
  - Muscular inactivity (injury, travel...)
  - Poor hydration
  - Limitation of venous blood flow (compression, joint flexion), procoagulant treatment.
- Direct action on the vein: physical (injections, massages), chemical (anabolizing agents, antibiotics, anti-inflammatory drugs, nutrients...)
3. Infection: streptococcus, staphylococcus, other
4. Susceptibility: deep vein insufficiency/varicose veins, coagulation disorder, immunological disease

Table 14b. Preventive measures

1. Assessment, diagnosis and treatment. Apply RICE measures (rest, ice, compression and elevation)
2. Movement and mobilisation of the area
3. Provide and ensure hydration
4. Prevent compression and limitation of the return blood flow
5. Avoid exacerbating the process with unnecessary or incorrect manipulation when it is only suspected
6. Treat the infection if indicated
7. Administer preventive LMWH if indicated. Individual assessment

The preventive measures are universal and all should be considered when faced with any risk factor.

4. Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. *Genetic Analysis of Idiopathic Thrombophilia*. *Am J Hum Genet*. 2000;67:1452-9.
5. Soria JM, Morange PE, Vila J, Souto JC, Moyano M, Trégouët DA, et al. Multilocus genetic risk scores for venous thromboembolism risk assessment. *J Am Heart Assoc*. 2014;3:e001060.
6. Rosendaal FR. Venous thrombosis: A multicausal disease. *Lancet*. 1999;353:1167-73.
7. Kearon C. Epidemiology of venous thromboembolism. *Semin Vasc Med*. 2001;1:7-26.
8. Useche JN, de Castro AM, Galvis GE, Mantilla RA, Ariza A. Use of US in the evaluation of patients with symptoms of deep venous thrombosis of the lower extremities. *Radiographics*. 2008;28:1785-97.
9. Wells PS, Hirsh J, Anderson DR, Lensing AWA, Foster G, Kearon C, et al. Accuracy of clinical assessment of deep-vein thrombosis. *Lancet*. 1995;345:1326-30.
10. Lozano F. Actualización en trombosis venosa profunda que afecta a las extremidades inferiores: diagnóstico. *Angiología*. 2003;55:476-87.
11. Geersing GJ, Zuihthoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: Individual patient data meta-analysis. *BMJ*. 2014;348:g1340.
12. Rubio-Terrés C, Soria JM, Morange PE, Souto JC, Suchon P, Mateo J, et al. Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism. *Appl Health Econ Health Policy*. 2015;13:233-42.
13. Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep venous thrombosis. Fallibility of clinical symptoms and signs. *Arch Surg*. 1976;111:34-6.
14. Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, de Maeseneer M, Hermesen JT, et al. Different accuracies of rapid enzyme-linked immunosorbent, turbidimetric, and agglutination D-dimer assays for thrombosis exclusion: Impact on diagnostic work-ups of outpatients with suspected deep vein thrombosis and pulmonary embolism. *Semin Thromb Hemost*. 2006;32:678-93.
15. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwiderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: A systematic review. *J Thromb Haemost*. 2007;5:296-304.
16. Wells PS. Integrated strategies for the diagnosis of venous thromboembolism. *J Thromb Haemost*. 2007;5 1 Suppl:41-50.
17. Aguilar C. Manual práctico para el empleo del Dímero D. Sociedad Española de Trombosis y Hemostasia (SETH); 2010.
18. Ho CH. Can very high level of D-dimer exclusively predict the presence of thromboembolic diseases? *J Chin Med Assoc*. 2011;74:151-4.
19. Aguilar C, del Villar V. Combined D-dimer and clinical probability are useful for exclusion of recurrent deep venous thrombosis. *Am J Hematol*. 2007;82:41-4.
20. Wells P, Anderson D. The diagnosis and treatment of venous thromboembolism. *Hematology Am Soc Hematol Educ Program*. 2013:457-63.
21. Fontcuberta García J, Samsó JJ, Senín Fernández ME, Vila Coll R, Escribano Ferrer JM. Actualización de la guía para el diagnóstico no invasivo de la insuficiencia venosa (I). Documento de consenso del capítulo de diagnóstico vascular de la Sociedad Española de Angiología y Cirugía Vascular. *Angiología*. 2015;67:125-32.
22. Comerota AJ, Katz ML, Hashemi HA. Venous duplex imaging for the diagnosis of acute deep venous thrombosis. *Haemostasis*. 1993;23 Suppl 1:61-71.
23. Cogo A, Lensing AW, Koopman MM, Piovella F, Siragusa S, Wells PS, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: Prospective cohort study. *BMJ*. 1998;316:17-20.
24. Martí-Mestre FX, Cairols-Castellote MA, Romera A, Herranz C. Diagnóstico en urgencias de la trombosis venosa de miembros inferiores: valor de los criterios clínicos unidos al dímero-D. *Angiología*. 2005;57:219-24.
25. Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. *N Engl J Med*. 2004;351:268-77.
26. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population based study. *Arch Intern Med*. 1998;158:585-93.
27. Venous Thromboembolic Diseases. The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing NICE Clinical Guidelines. No. 144 National Clinical Guideline Centre (UK). London: Royal College of Physicians (UK); 2012.
28. Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. *Rev Esp Cardiol Supl*. 2013;13:33-41.
29. Martí-Fàbregas J, Delgado-Mederos R, Mateo J. Limitations of anticoagulant therapy. *Neurologia*. 2012;27 1 Suppl:27-32.
30. Partsch H, Blättler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. *J Vasc Surg*. 2000;32:861-9.
31. Depenbrock PJ. Thromboembolic disorders: Guidance for return-to-play. *Curr Sports Med Rep*. 2011;10:78-83.
32. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al. The epidemiology of venous thromboembolism in the community. *Thromb Haemost*. 2001;86:452-63.
33. Lowe GDO. Blood rheology and venous thrombosis. *Clin Hemorheol*. 1984;4:571-88.
34. Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. *Br J Haematol*. 2011;152:31-4.
35. Fuchs S, Heyse T, Rudofsky G, Gosheger G, Chylarecki C. Continuous passive motion in the prevention of deep-vein thrombosis. A randomised comparison in trauma patients. *J Bone Joint Surg*. 2005;87B:1117-22.
36. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2001. Oxford: Update software.
37. Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study, European Concerted Action on Thrombosis. *Thromb Haemost*. 1999;81: 879-86.
38. Nilsson-Helander K, Thurin A, Karlsson J, Eriksson BI. High incidence of deep venous thrombosis after Achilles tendon rupture: A prospective study. *Knee Surg Sports Traumatol Arthrosc*. 2009;17:1234-8.
39. Graham WC, Flanigan DC. Venous thromboembolism following arthroscopic knee surgery: A current concepts review of incidence, prophylaxis, and preoperative risk assessment. *Sports Med*. 2014;44:331-43.
40. Dong JT, Wang X, Men XQ, Wang XF, Zheng XZ, Gao SJ. Incidence of deep venous thrombosis in Chinese patients undergoing arthroscopic knee surgery for cruciate ligament reconstruction. *Knee Surg Sports Traumatol Arthrosc*. 2014 [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/25362246>

41. Suárez C. Síndrome de la clase turista. *Med Clin (Barc)*. 2002;119:16-7.
42. Gupta N, Ashraf MZ. Exposure to high altitude: A risk factor for venous thromboembolism? *Semin Thromb Hemost*. 2012;38:156-63.
43. Lippi G, Banfi G. Doping and thrombosis in sports. *Semin Thromb Hemost*. 2011;37:918-28.
44. Vilalta N, Souto JC. Investigación de la trombofilia venosa. Presente y futuro. *Angiología*. 2014;66:190-8.
45. Field TS, Hill MD. Prevention of deep vein thrombosis and pulmonary embolism in patients with stroke. *Clin Appl Thromb Hemost*. 2012;18:5-19.
46. Casals M, Martínez JA, Caylà JA, Martín V. Do basketball players have a high risk of pulmonary embolism? A scoping review. *Med Sci Sports Exerc*. 2015 Oct 2 [Epub ahead of print].
47. Drobic F, Gudelis M, Peirau X, Til L. Prevalencia de enfermedad tromboembólica venosa en el fútbol profesional. Estudio retrospectivo de 10 años en primera y segunda división en España. Personal communication, 2015.